anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is a longitudinal cohort follow-up study. The main contents include:(1)Questionnaire design: questionnaire is designed according to the research contents and purposes. The standard questionnaires will be used to collect the general information, dietary habits, lifestyle, medical history and family history etc.(2)Anthropometric measurements: blood pressure, height, body weight,waist and hip, pulse will be acquired by medical practitioners who received professional trainings based on World Health Organization (WHO) standards, and passed relevant examinations.(3) Blood and urine samples collection: morning fasting blood, nocturia, and 24-hour urine specimen will be collected by medical staffs, and blind tubes will be set up according to 5% of the total samples. Blood biochemistries including serum total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, fasting glucose, creatinine and hsCRP can be measured using automatic biochemical analyzer. The sodium and potassium concentrations in the urine will be measured by flame photometry. The total sodium and potassium excretions in urine in 24h were calculated by multiplying the concentration and 24-h volume of urine. (4) Auxiliary examinations: Auxiliary examinations including carotid intima-media thickness, endothelium-dependent vasodilation (FMD), measurements of brachial-ankle pulse wave velocity (baPWV) and electrocardiographic parameters. The measurement will be done in hospitals by medical practitioners who received professional trainings and passed relevant examinations. (5) Single nucleotide polymorphisms detection: based on our previous studies, sodium and potassium metabolism-related gene polymorphisms will be detected using MassARRAY technology. (6) Data processing and statistics: we should input the data to the database, and utilize softwares such as SPSS, STATA, Haploview and FBAT to analyze. (7) Quality control: ① Questionnaire is strictly designed and amended by epidemiologist and clinical experts. ② A standardized "Investigator Handbook" will be stipulated according to the guidelines. ③ Staff members are required to do a rigorous training and pass the exam. ④ The investigation process will be strictly supervised by the principal investigator. ⑤ Data entry use the parallel double entry method. ⑥ During laboratory testing, blank control and blind detection are applied to ensure the quality. ⑦ Data analysis is performed by 2-3 postgraduates, inconsistent data need to be double checked.
The application provides a preparation method of high-activity black ginseng, which comprises the following steps: cleaning fresh ginseng; soaking ginseng in water bath with compound enzyme, and performing constant temperature enzymolysis with the assistance of ultrasound; steaming Ginseng radix subjected to constant temperature enzymolysis; by supercritical CO  2  The technology is to dry the steamed ginseng. Beta-glucosidase and cellulase in the ratio of 2-5: 1-3. Soaking Ginseng radix in water bath at 35-45deg.C with compound enzyme, and performing constant temperature enzymolysis with 50-100W power ultrasound. The steaming medium is 1-20% acetic acid aqueous solution. Steaming the ginseng subjected to constant temperature enzymolysis for 3-5h. The application is different from the existing black ginseng processing technology, adopts constant temperature low frequency ultrasonic auxiliary enzymolysis, low concentration acetic acid aqueous solution steaming and supercritical CO  2  The drying technology shortens the drying process time, reduces the drying temperature, effectively improves the production efficiency, and ensures that the content of rare saponin Rg3 in the black ginseng is obviously higher than that in the black ginseng manufactured by the traditional processThe Rg3 content ensures the bioactivity of the black ginseng to the greatest extent.
BACKGROUND: Stroke remains the second leading cause of death worldwide, with a 20 % risk of recurrence within 5 years. Preventing secondary stroke events is crucial for patient management. Kraft et al. highlighted the potential of telemedicine in secondary prevention, but noted the need for further research. Our study incorporates recent trials to provide an updated analysis of telemedical strategies in stroke prevention.
METHODS: We reviewed and analyzed RCTs and observational studies from PubMed, Cochrane, Google Scholar, and Clinicaltrials.gov (May 19, 2016 - March 20, 2024) comparing telephone-based follow-up to standard care in stroke patients. The meta-analysis focused on SBP changes within 12 months. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies, sourced from PubMed, Cochrane, Google Scholar, and ClinicalTrials.gov (May 19, 2016 - March 20, 2024). We compared telephone-based follow-up to standard care in stroke patients, and the primary outcome was systolic blood pressure (SBP) changes within 12 months.
RESULTS: Our systematic review included data from 21,904 patients. The meta-analysis focused on studies with comparable systolic blood pressure (SBP) data. It involved 3,501 individuals in the control group and 3,485 in the experimental group. The analysis revealed a significant reduction in SBP with telemedicine strategies for secondary stroke prevention, with a p-value of 0.003. Additionally, a systemic review of the included studies demonstrated that these strategies improved medication adherence, lifestyle habits, and physical performance, positively correlating with better health outcomes and reduced mortality risk.
CONCLUSION: With the inclusion of recent clinical trials, our updated systematic review and meta-analysis concludes that telemedicine supports secondary prevention in cerebrovascular diseases, particularly blood pressure control. While telemedicine may have a role in reducing recurrent stroke risk, we believe further studies with longer follow-up periods are needed to validate the role of telemedical strategies in reducing recurrence rates.
Patients in this group received a bovine xenograft in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so no future patients will receive the bovine xenograft during the procedure.
PROBLEM TO BE SOLVED: To prepare the subject treatment agent capable of preventing hair from damaging due to cold perming, etc., capable of giving hair good touch and capable of improving the wave-forming ability and a straightening effect by including both cystine and keratin hydrolyzate having cystine residue. SOLUTION: This treatment agent is prepared by blending (A) cystine with (B) keratin hydrolyzate having cystine residue and/or plant extract containing cystine residue. It is pref. that (C) a cationic surfactant and/or a cationic polymer of the formula (R1 and R2 are each a 1-3C alkyl, hydroxyalkyl, or the like; R3 and R4 are each a 8-22C alkyl, an alkenyl, or the like; X is a halogen, methylsulfate, or the like), esp. pref. a quaternary nitrogen-containing cationic polymer are included as an additional ingredient.
Nonalcoholic fatty liver disease (NAFLD), which encompasses a spectrum from simple steatosis and steatohepatitis (NASH) to fibrosis and cirrhosis, is the leading cause of liver disease in the United States. There are currently no FDA-approved pharmacologic therapies for NAFLD and NASH, and standard low-calorie diets are often minimally effective, difficult to adhere to and to maintain. Thus, continued investigation of strategies to treat NAFLD and NASH is greatly needed. Non-obese NAFLD (BMI\<30kg/m2) is an increasingly recognized condition, sometimes described as "lean NAFLD". It is estimated that 10-20% of American and Europeans without obesity have this condition. There is a pressing need for the study of lifestyle interventions independent of weight loss to treat this important subset of NAFLD patients. This protocol aims to investigate the utility of time restricted, intermittent fasting (TRF) as a potential method. Adults with non-obese NAFLD are at risk of progression to end-stage liver disease and development of cardiometabolic disease. Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. IF is characterized by periods of dietary restriction leading to metabolic production and use of ketones from adipocytes rather than hepatically-derived glucose.

The goal of this study is to learn if time-restricted, intermittent fasting can help reduce the amount of fat in the liver in adults with non-alcoholic fatty liver disease (NAFLD). Ideally, this study will yield more information about time-restricted, intermittent fasting as a potential lifestyle-based treatment for adults with NAFLD and a body mass index (BMI) between 23-30 kg/m\^2.
The present invention relates to a medicine for treating femoral head necrosis and a preparing method thereof. The medicine for treating femoral head necrosis belongs to the field of a traditional Chinese medicine. The medicine for treating femoral head necrosis is mainly prepared by mixing fourteen traditional Chinese medicines, such as nux vomica, licorice roots, pangolin, barberry roots, huaxue, spatholobus stems, achyranthes roots, mahonia, etc., in certain mixing proportions. A conventional method of Chinese medicine preparations can be adopted to add different auxiliary materials into active medical powder to prepare different conventional Chinese medicine preparations, such as tablets, pills, capsules or oral liquid. The medicine of the present invention performs the actions of rheumatic pain expelling, dampness removal, inflammation relieving, pain alleviation, blood circulation activation, blood stasis dissipation, and meridian and collateral clearing. The medicine of the present invention has remarkable effect on treatment of the femoral head necrosis and also has good therapeutic effect on rheumatic bone and muscle pain, numb limbs and tense tendons, lumbar disk herniation, hyperosteogeny, sciatic neuralgia, arthritis and traumatic injury.
NEW MATERIAL:T-5310 (salt) having the following characteristics. Inhibits the multiplication of sarcoma 180 and has an immunostimulating activity. Insoluble in many organic solvents. The molecular weight is 1000 to 50000. The isoelectric point is near 11. Positive on a phenol sulfuric acid reaction, anthrone sulfuric acid reaction, Lowry.Folin reaction and ninhydrin reaction. Elementary analysis; C: 30 to 35%, N: 2 to 4% and H: 5 to 7%. The saccharide content: 40 to 60% and the protein content: <=15%. Limulus test is negative. EXAMPLE:An antitumor agent and an immunostimulating agent. USE:The T-5310 is prepared by dissolving TF-310, etc., collected from the culture solution of a bacterium belonging to the genus Fusobacterium, etc., in Ampholine having a pH of 3.5 to 10, treating the solution with a linear gradient mixer and fractionating the treated solution by an isoelectric point electrophoresis employing a column filled with a filler therein in a state having a sucrose density gradient, followed by collecting a fraction having an isoelectric point of 9 to 12.5 to provide the T-5310.
Hypertensive intracerebral hemorrhage (HICH) is a destructive disease with high mortality, incidence, and disability. Asiaticoside (AC) is a triterpenoid derivative that has demonstrated to exert a protective effect on neuron and blood vessel. To investigate the function and potential mechanism of AC on HICH. Human brain microvascular endothelial cells (hBMECs) were treated with 20 U/mL thrombin for 24 h to establish the HICH model in vitro, and AC with the concentration of 1, 2 and 4 µM were used to incubate hBMECs. The effect and potential mechanism of AC on HICH were investigated by using cell counting kit-8, flow cytometry, tube forming assays, vascular permeability experiments and western blot assays. In vivo, rats were injected with 20 µL hemoglobin with a concentration of 150 mg/mL, and then intragastrically administrated with 1.25, 2.5 and 5 mg/kg AC. Behavioral tests, brain water content measurement, hematoxylin-eosin (HE) staining, terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick end labeling assays, and western blot were used to assess the effect and potential mechanism of AC on HICH. AC (at 2 and 4 µM) improved the proliferation, apoptosis, angiogenesis and vascular permeability in thrombin-induced hBMECs (p < 0.05). Besides, AC (2.5 and 5 mg/kg) ameliorated behavioral scores, brain water content, pathological lesion, apoptosis and the expression of vascular permeability-related proteins in rats with HICH (p < 0.05). In addition, AC elevated the expression of PI3K/AKT pathway after HICH both in cell and animal models (p < 0.05). Application of LY294002, an inhibitor of PI3K/AKT pathway, reversed the ameliorative effect of AC on the proliferation, apoptosis, angiogenesis and vascular permeability in thrombin-induced hBMECs (p < 0.05). AC reduced brain damage by increasing the expression of the PI3K/AKT pathway after HICH.
Influenza has been identified as a major health problem in young children. Influenza related hospitalizations are very high in children less than 24 months of age and children age 24-59 months have a high rate of medical care utilization due to influenza. Recently, it has been noted that there are deaths attributable to influenza even in previously healthy children. Recent CDC recommendations reflect this growing awareness of the impact of influenza in children and state that virtually all children less than 18 years of age should receive annual influenza vaccination.

Currently available licensed trivalent influenza vaccines (TIVs) are prepared from viruses that are grown in embryonated hens' eggs. Alternative substrates for vaccine production are desirable in order to reduce the vulnerability of and to expand influenza vaccine supply. Recombinant DNA techniques allow for expression of the influenza hemagglutinin (rHA) by baculovirus vectors in insect cell cultures. Advantages of this technique include speed of production, absence of egg protein, and a highly purified product.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. 

In 2 randomized, double-blind, vehicle-controlled trials, subjects age 9 years and older applied ALTRENO or vehicle once daily for 12 weeks. The majority of subjects were White (74%) and female (55%). Approximately 47% were Hispanic/Latino and 45% were younger than 18 years of age. Adverse reactions reported by ≥1% of subjects treated with ALTRENO and more frequently than vehicle are summarized in Table 1.

Skin irritation was evaluated by active assessment of erythema, scaling, hypopigmentation, hyperpigmentation, itching, burning and stinging. The percentage of subjects who were assessed to have these signs and symptoms at any post baseline visit are summarized in Table 2.
This group will consist of participants ages 1 - 7. The subject who are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
PROBLEM TO BE SOLVED: To obtain a flavor tasted dental product with a coating film to prevent fraying and shredding of a substrate by forming a water insoluble coating film on a monofilament substrate and giving a flavor taste material and a flavor taste enhancing agent on the outer face and within the thickness of the coating film. SOLUTION: A floss substrate 200 taken out from a rewinding roll 410 is passed through a dying station 420 to apply a coating composition containing a flavor taste material and a flavor taste enhancing agent in a melting state on the outer face. The dying station 420 is equipped with a V-groove for passing the floss substrate 200. A heating supply tank 430 is connected to an opening formed in the bottom of the V-groove through a coating pump 440. The coated floss is dried and set thereafter and wound at a take-out roll in a rewinding station 470. At that time, the speed of the floss 200 is monitored by a speed sensor 450 and a pump 440, etc., are controlled by a controller 460.
An aqueous ACTH mixture or solution of enhanced potency as manifested upon subcutaneous administration is prepared by heating, from 50 DEG to 150 DEG C., an aqueous mixture containing ACTH at a pH of from 4,5 to 8,0.  The mixture preferably contains a reducing agent containing at least one sulphhydryl group such as hydrogen sulphide, beta mercaptoethanol, thioglycollic acid or preferably cysteine.  Any mammalion pituitary tissue, such as bovine, ovine, porcine, may be used as the source of the aqueous mixture and the pH may be adjusted by agents such as sodium hydroxide or trisodium phosphate.  The addition of gelatin increases the rate at which the ACTH potency is enhanced at any temperature, this rate generally increasing as the temperature is increased, although the maximum enhancement attainable may be lessened.  As a result of heating the major portion of the ACTH goes into solution.  The insoluble residue may be removed by filtration or centrifugation and the solution used as a therapeutic preparation or further purified.  Specification 818,248 is referred to.
Bile duct injury (BDI) post cholecystectomy is an iatrogenic catastrophe associated with significant morbidity , mortality and poor quality of life this is due to the large number of cholecystectomies per year all over the world. Cholecystectomy whether open or laparoscopic is done in large number about 750,000 annually in USA, the incidence of BDI post cholecystectomy is about 0.1-0.2% in open cholecystectomy and 0.4-0.6% in laparoscopic cholecystectomy although the percentage appears small but it still large number about 2100 patients per year. The two most frequent scenarios of BDI may be occurrence of bile leak or bile duct obstruction. Early recognition of iatrogenic bile duct injury is essential to prevent major morbidity by imaging techniques, such as Ultrasound and CT which are extremely valuable during the initial evaluation but MRCP remains the gold standard for diagnosis. ERCP can confirm the presence of biliary injury and provides a means for definitive management. The main aim of surgical treatment is the reconstruction of proper flow of bile to the alimentary tract. Repair of such injuries still remains a challenge due to the variety of size of injury, site of injury if proximal or distal, the severity of injury and the time of presentation after the injury. Repair of such BDI may be done by laparoscopy or by open surgery which still a matter of debate. There are many described techniques should be done by specialized hepatobiliary surgeon from simple repair, repair over T-tube up to hepaticojejunostomy. Despite widespread advances in laparoscopic surgery, laparoscopic repair of post-cholecystectomy bile duct injury (BDI) has rarely been reported related mainly to technical difficulty.
Limited research has been done on the effects of gender and menstrual cycle in response to drugs of abuse in humans. The main goal of this pilot study is to investigate the safety and tolerability of progesterone treatment in female nicotine users. In addition, plasma progesterone levels reached with a single 200 mg dose of progesterone treatment will be measured. The study will be a double-blind placebo controlled, crossover trial in which 12 female smokers who are in the early follicular phase of their menstrual cycle will be enrolled. Druing the experimental sessions, subjects will be given a single 200 mg dose of micronized progesterone or placebo and multiple blood samples will be obtained to measure the plasma levels of progesterone. Starting 2 hours after progesterone or placebo treatment, subjects will have a self-administration period that will last around 2.5 hours. We hypothesize that administration of 200 mg of progesterone will achieve plasma progesterone concentrations similar to those found in the luteal phase of the menstrual cycle, 3-30 ng/ml.
Follicular fluid meiosis-activating sterol (FF-MAS) is a small molecule compound found in FF, named for its ability to induce oocyte resumption of meiosis. Granulosa cells (GCs) within the follicle are typically located in a hypoxic environment under physiologic conditions due to limited vascular distribution. Previous research suggests that hypoxia-induced cell cycle arrest and apoptosis in GCs may be crucial triggering factors in porcine follicular atresia. However, the impact of FF-MAS on GCs within follicles has not been explored so far. In this study, we uncovered a novel role of FF-MAS in facilitating GC survival under hypoxic conditions by inhibiting STAT4 expression. We found that STAT4 expression was upregulated in porcine GCs exposed to 1% O2. Both gain and loss of function assays confirmed that STAT4 was required for cell apoptosis under hypoxia conditions, and that the GC apoptosis caused by hypoxia was markedly attenuated following FF-MAS treatment through inhibition of STAT4 expression. Correlation analysis in vivo revealed that GC apoptosis was associated with increased STAT4 expression, while the FF-MAS content in follicular fluid was negatively correlated with STAT4 mRNA levels and cell apoptosis. These findings elucidate a novel role of FF-MAS-mediated protection of GCs by inhibiting STAT4 expression under hypoxia, which might contribute to the mechanistic understanding of follicular development.
Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.
PURPOSE: A method for preparing a mixture extract of Adansonia digitata, Lithospermum erythrorhizon Siebold and Zuccarini, Dioscorea japonica Thunberg, and lotus roots and a cosmetic composition containing the extract are provided to ensure excellent anti-inflammatory and anti-allergic effects. CONSTITUTION: A cosmetic composition contains a mixture extract of Adansonia digitata, Lithospermum erythrorhizon Siebold and Zuccarini, Dioscorea japonica Thunberg, and lotus roots. The cosmetic composition is prepared by fermentation using Bacillus sp. The extract is prepared using a mixture solvent of purified water, C1-C43 alcohol, hydrous C1-C4 alcohol, C1-C6 glycol, hydrous C1-C6 glycol, ethyl acetate, benzene, hexane, diethyl ether, or dichloromethane. The cosmetic composition is manufactured in the form of a lotion, a nutrition cream, a massage cream, an essence, or a pack. [Reference numerals] (AA) Adansonia digitata; (BB) Lithospermum erythrorhizon Siebold and Zuccarini; (CC) Dioscorea japonica Thunberg; (DD) Lotus root; (EE) Mixed extract
Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be MitoQ. Testing will take place forty-minutes after placebo/MitoQ intake. There will be a 2-week washout between testing days.